Saturday 17 October 2026
Export PMN’s income statement to Excel — free account
Promis Neurosciences
In the quarter to June 2026, EPS grew 82.3% and free cash flow fell 169.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.15
0.55
−6.32%
Follow PMN
Promis Neurosciences (PMN) P/E ratio
Promis Neurosciences has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2020 | 0.0× | — |
| Jun 2020 | 0.0× | — |
| Dec 2019 | 0.0× | — |
| Sep 2019 | 0.0× | — |
| 7 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACRV Acrivon Therapeutics, Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| PTHS Pelthos Therapeutics Inc. compare | n/m |
| OKYO OKYO Pharma Limited Sponsored ADR compare | n/m |
| CLLS Cellectis S.A. compare | n/m |
| NMRA Neumora Therapeutics, Inc. compare | n/m |
| NTRB Nutriband Inc. compare | n/m |
| CRDF Cardiff Oncology, Inc. compare | n/m |
| PMN Promis Neurosciences | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)